🔎 Trials Near Me

Beranda › Limfoma Sel B › New York

Uji klinis Limfoma Sel B di New York

21 studi untuk Limfoma Sel B mencari peserta di lokasi di New York.

Kota di New York

Teks studi resmi (Bahasa Inggris)

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  • Memorial Sloan Kettering Cancer Center Mskcc, New York
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06742996

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • New York University (NYU) Clinical Cancer Center, New York
  • Weill Cornell Medicine, New York
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • The Mount Sinai Hospital, New York
Menerima pesertaFase 1
Usia 0 hingga 18 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06173518

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, New York
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06526793

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

  • Icahn School of Medicine At Mount Sinai, New York
  • Columbia University Medical Center, New York
  • Weill Cornell Medical College Newyork Presbyterian Hospital, New York
  • dan 2 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06634589

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

  • NYU Langone Hospital - Long Island, Mineola
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT05272384

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  • Research Site, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06564038

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

  • Clinical Trial Site, New York
  • Clinical Trial Site, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06393738

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  • Research Site, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07123454

A Study of ARC-02 in B-cell NHL

  • NYU Langone, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, The Bronx
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

  • Research Site, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT07220616

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Roswell Park Comprehensive Cancer Center, Buffalo
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

  • Memorial Sloan Kettering, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT05463263

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

  • Columbia University Irving Medical Center, New York
Menerima pesertaFase 2
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT06954805

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

  • New York Medical Center, Valhalla
Menerima pesertaFase 1/2
Usia 12 hingga 70 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04491370

Study of CAR-T Therapy in Older Patients

  • Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaStudi observasional
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 7 Apr 2026 · NCT04300998

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

  • Columbia University, New York
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jan 2026 · NCT06693830

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

  • Memorial Sloan Kettering Cancer Center (All protocol activities), New York
  • NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Okt 2025 · NCT05940272

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital New York-Presbyterian, New York
  • Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.